Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
ID | Components | Size |
ADC-P008-C01 | 20 x Reaction buffer | 50ul |
ADC-P008-C02 | Cofactor A | 50ul |
ADC-P008-C03 | Cofactor B | 50ul |
ADC-P008-C04 | Substrate A | 25ul |
ADC-P008-C05 | Substrate B | 25ul |
ADC-P008-C06 | Enzyme A | 25ul |
ADC-P008-C07 | Enzyme B | 25ul |
ADC-P008-C08 | Enzyme C | 20ul |
ID | Components | Size |
ADC-P008-1-C01 | Binding buffer | 15ml |
ADC-P008-1-C02 | Elution buffer | 1.5ml |
ADC-P008-1-C03 | Neutralization buffer | 0.5ml |
ADC-P008-1-C04 | 250 mM Tris-HCl buffer (pH7.5) | 1.5ml |
ADC-P008-1-C05 | 10×PBS (pH7.2- 7.4) | 6ml |
ADC-P008-1-C06 | Desalting column | 2per |
ADC-P008-1-C07 | Concentrator tube | 2per |
ADC-P008-1-C08 | ProteinA Resin | 100ul*2 |
AGLink® ADC Conjugation Kit (Biotin, DAR2&4, 1mg) is designed to conjugate 1mg mAb with Biotin through site-specific enzymatic reaction.
It is for research use only.
Almost all monoclonal antibodies are glycosylated at (or around) Asn-297 of the Fc domain. While the glycans have different isoforms, the types that typically dominate are G0F, G1F&G2F (>90%). The A&Glink® Antibody Conjugation Kit utilizes the YTConju™ platform, a glycan remodeling strategy developed by Glyco-therapy Biotechnology Co., Ltd. for the construction of site-specific antibody conjugates.
The A&Glink® DAR2&4 Antibody Conjugation Kit integrates the procedure for constructing DAR2 conjugates and DAR4 conjugates in one kit, providing flexibility in DAR design.
To construct the DAR4 conjugates, galactose is first added to the terminal GlcNAc catalyzed by β-1,4-galactosyltransferase (GT) to form LacNAc. Then, α-1,3-fucosyltransferase (FT) recognizes LacNAc and transfers the Fuc-Payload to the GlcNAc of the LacNAc to form a conjugate with a theoretical DAR of 4.
To construct the DAR2 conjugates, glycans are first removed from the core GlcNAc catalyzed by endoglycosidase. Galactose is then added to the GlcNAc catalyzed by β-1,4-galactosyltransferase (GT) to form core LacNAc. Finally, α-1,3-fucosyltransferase (FT) recognizes LacNAc and transfers the Fuc-Payload to the GlcNAc of the LacNAc to form a conjugate with a theoretical DAR of 2.
The DAR4 and DAR2 conjugation procedures share the same FT, GT and GDP-Fuc-Payload. The main difference between these two procedures is the addition of an endoglycosidase.
These procedures are performed in a “one-pot” manner with only one purification step, which is highly convenient and efficient. Antibody conjugates produced with this kit generally exhibit high homogeneity, high stability and high hydrophilicity.
ADC DAR value assessment by LC-TOF/MS
1.Analyst TF 1.8.1 Software was used to collect LC-TOF/MS data of samples in positive ion mode
2.PeakView was used for data processing and BioToolKit was used for deconvolution analysis.
3.DAR values are calculated using the following formula:
DAR4 =(920.12*4+77.42*3)/(920.12+77.42)=3.92
ADC DAR value assessment by LC-TOF/MS
1.Analyst TF 1.8.1 Software was used to collect LC-TOF/MS data of samples in positive ion mode
2.PeakView was used for data processing and BioToolKit was used for deconvolution analysis.
3.DAR values are calculated using the following formula:
DAR4 =(1138.27*2)/1138.27=2.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
This web search service is supported by Google Inc.